Polymyxin B hemoperfusion as a feasible therapy after source control in abdominal septic shock

Table 3 Comparative analysis of variables changes between baseline and 72 h after treatment

Patients	PMX-HP (n = 20)		Control (n = 20)		P value
	To1	T722	To3	T724
SOFA score	11.2 ± 5.8	4.7 ± 3.5	10.0 ± 4.0	8.7 ± 7.3	0.047a
Respiratory SOFA	2.6 ± 1.0	1.9 ± 1.0	2.6 ± 1.5	1.8 ± 1.0	0.799
Cardiovascular SOFA	3.4 ± 1.2	0.4 ± 0.9	2.3 ± 1.8	1.2 ± 1.3	0.072
Liver SOFA	0.7 ± 0.9	1.1 ± 1.5	0.7 ± 1.3	1.4 ± 1.3	0.683
Renal SOFA	2.6 ± 1.0	0.7 ± 1.0	2.6 ± 1.5	2.8 ± 1.6	0.000a
Coagulation SOFA	1.6 ± 1.5	1.3 ± 1.3	1.2 ± 1.2	2.8 ± 1.8	0.014a
WBC, 109/L	87.7 ± 65.0	102.5 ± 62.7	94.0 ± 49.1	115.6 ± 59.0	0.552
Hb, g/L	9.6 ± 2.0	9.0 ± 0.9	10.5 ± 2.2	9.7 ± 1.0	0.024a
Inotropic score	163.7 ± 302.1	8.9 ± 19.1	90.8 ± 181.7	1.4 ± 4.2	0.006a
VDI	2.4 ± 3.4	0.1 ± 0.3	1.0 ± 2.0	0.0 ± 0.1	0.001a

¹Immediately after completion of two session of polymyxin B hemoperfusion (PMX-HP);

²Seventy-two hours after completion of two session of PMX-HP;

³Immediately after surgical control;

⁴Seventy-two hours after conventional standard therapy according to survival sepsis campaign.

^aP < 0.05, compared with variables between just before initiating treatment and 72 h after initiating the treatment in PMX-HP group and control group. SOFA: Sequential organ failure assessment; WBC: White blood cell; Hb: Hemoglobin; VDI: Vasopressor dependency index; PMX-HP: Polymyxin B hemoperfusion.